NuVasive, Inc. , a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that it has signed a definitive agreement to acquire the Osteocel biologics business from Osiris Therapeutics, Inc. .
NuVasive signs definitive agreement to acquire Osteocel biologics business from Osiris Therapeutics